397 related articles for article (PubMed ID: 32357417)
1. Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers.
Kailayangiri S; Altvater B; Wiebel M; Jamitzky S; Rossig C
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32357417
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
3. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
4. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS
Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494
[TBL] [Abstract][Full Text] [Related]
5. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
Ebert LM; Yu W; Gargett T; Brown MP
Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
[TBL] [Abstract][Full Text] [Related]
6. Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating.
Hamieh M; Mansilla-Soto J; Rivière I; Sadelain M
Cancer Discov; 2023 Apr; 13(4):829-843. PubMed ID: 36961206
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer.
Petty AJ; Heyman B; Yang Y
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32244520
[TBL] [Abstract][Full Text] [Related]
8. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2017; 8():1850. PubMed ID: 29312333
[TBL] [Abstract][Full Text] [Related]
10. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
[TBL] [Abstract][Full Text] [Related]
11. A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.
Goulding J; Yeh WI; Hancock B; Blum R; Xu T; Yang BH; Chang CW; Groff B; Avramis E; Pribadi M; Pan Y; Chu HY; Sikaroodi S; Fong L; Brookhouser N; Dailey T; Meza M; Denholtz M; Diaz E; Martin J; Szabo P; Cooley S; Ferrari de Andrade L; Lee TT; Bjordahl R; Wucherpfennig KW; Valamehr B
Med; 2023 Jul; 4(7):457-477.e8. PubMed ID: 37172578
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
Hughes-Parry HE; Cross RS; Jenkins MR
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
[TBL] [Abstract][Full Text] [Related]
13. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
14. New development in CAR-T cell therapy.
Wang Z; Wu Z; Liu Y; Han W
J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
[TBL] [Abstract][Full Text] [Related]
15. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.
Gao TA; Chen YY
Annu Rev Chem Biomol Eng; 2022 Jun; 13():193-216. PubMed ID: 35700528
[TBL] [Abstract][Full Text] [Related]
16. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
17. Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.
Klampatsa A; Leibowitz MS; Sun J; Liousia M; Arguiri E; Albelda SM
Mol Ther Oncolytics; 2020 Sep; 18():360-371. PubMed ID: 32802940
[TBL] [Abstract][Full Text] [Related]
18. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
[TBL] [Abstract][Full Text] [Related]
19. Innovative strategies to advance CAR T cell therapy for solid tumors.
Huang M; Deng J; Gao L; Zhou J
Am J Cancer Res; 2020; 10(7):1979-1992. PubMed ID: 32774996
[TBL] [Abstract][Full Text] [Related]
20. Multi-Specific CAR Targeting to Prevent Antigen Escape.
Walsh Z; Ross S; Fry TJ
Curr Hematol Malig Rep; 2019 Oct; 14(5):451-459. PubMed ID: 31332617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
